


BRAZIL

Cutaneous and mucosal Leishmaniasis 2017

Incidence (100,000 pop.) **17.7**
 Transmission **Very Intense**
 Triennium Leishmaniasis Composite Indicator (TLCIc 2015-2017)



LCIc triennium* (2015-2017)



*The MoH reported 1297 cases from unknown municipalities that were not included in the leishmaniasis composite indicator analysis.

Occurrence

17526

NEW CASES

16708 cutaneous (95.3%)

818 mucosal (4.7%)



AGE GROUP

3.2% < 5 Y/O
 4% ≥ 5 < 10 Y/O
 91.8% > 10 Y/O
 1% Unspecified

7.2% children under 10 years old



GENDER

72.7% Male
 27.3% Female

56.4% men over 20 years old



CROSS-BORDER

Shares borders with **10** countries in **588** municipalities

16.3% of the cases at the borders



SURVEILLANCE AND CONTROL

47.6% of the population in transmission areas

Maintained the % of CL in children under 10 Y/O compared to the 2012-2015 baseline (Targets of the Plan of Action)



LEISHMANIA SPECIES

L. amazonensis
L. braziliensis
L. guyanensis
L. lainsoni
L. lindenbergi
L. naiffi
L. shawi



LUTZOMYIA VECTORS

L. flaviscutellata, *L. reducta*, *L. olmeca nociva*, *L. whitmani*, *L. neivai*, *L. migonei*, *L. carrerai carrerai*, *L. intermedia*, *L. complexa*, *L. wellcomei*, *L. davisii*, *L. fischeri*, *L. pessoai*, *L. umbratilis*, *L. anduzei*, *L. ubiquitousis*, *L. antunesi*, *L. ayrozai*, *L. squamiventris*, *L. paraensis*, *L. edwardsi*, *L. amazonensis*



PATIENT ASSISTANCE

Laboratory confirmation: **83.1%**

Cure rate: **69.8%**

% of cured patients among the treated: **74.1%**



AVAILABLE MEDICINE

Meglumine Antimoniate

Deoxycholate Amphotericin B

Liposomal Amphotericin B

Pentamidine Isethionate

Source:

SisLeish - PAHO/WHO - Data provided by the Ministries of Health - National Leishmaniasis Programs
 Accessed on: 01 November 2018.

N/O: No information available; Y/O: years old